Literature DB >> 25927447

Erratum: A randomized, double-blind, placebo-controlled study of rapid-acting intramuscular olanzapine in Japanese patients for schizophrenia with acute agitation.

Hideaki Katagiri1, Shinji Fujikoshi2, Takuya Suzuki3, Kiyoshi Fujita4, Naoya Sugiyama5, Michihiro Takahashi6,7, Juan-Carlos Gomez8.   

Abstract

Entities:  

Year:  2014        PMID: 25927447      PMCID: PMC4260377          DOI: 10.1186/s12888-014-0313-9

Source DB:  PubMed          Journal:  BMC Psychiatry        ISSN: 1471-244X            Impact factor:   3.630


× No keyword cloud information.

Correction

After the publication of this work [1], we became aware that it contains inaccurate description. The correct description on page 5 was “At every timepoint, statistically significant differences were observed between IM olanzapine and IM placebo groups (p < .01) (Figure one)”, and not “At every timepoint, statistically significant differences were observed between IM olanzapine and IM placebo groups (p < .001) (Figure one).” We regret any inconvenience that this inaccuracy might have caused.
  1 in total

1.  A randomized, double-blind, placebo-controlled study of rapid-acting intramuscular olanzapine in Japanese patients for schizophrenia with acute agitation.

Authors:  Hideaki Katagiri; Shinji Fujikoshi; Takuya Suzuki; Kiyoshi Fujita; Naoya Sugiyama; Michihiro Takahashi; Juan-Carlos Gomez
Journal:  BMC Psychiatry       Date:  2013-01-11       Impact factor: 3.630

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.